Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01494233 · ClinicalTrials.gov registry record · Phase 2

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

A Phase 2 study of Irritable Bowel Syndrome, sponsored by Lexicon Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
373
Enrollment target
20
Study locations

NCT01494233 is a Phase 2 study of Irritable Bowel Syndrome that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 373 participants, above the 136-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (174% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01494233, a Phase 2 study of Irritable Bowel Syndrome, has completed, sponsored by Lexicon Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
373 participants
Enrollment target
20
Study locations

Study Summary

The objective of this study is to evaluate the safety and efficacy of LX1033 over a range of dose levels in subjects with diarrhea-predominant Irritable Bowel Syndrome (IBS).

Conditions Studied

Irritable Bowel Syndrome

Interventions

  • DRUG Placebo tablet
  • DRUG 250 mg LX1033 tablets

Study Locations (20)

California

  • Lexicon Investigational Site - Anaheim
  • Lexicon Investigational Site - Encinitas
  • Lexicon Investigational Site - Los Angeles
  • Lexicon Investigational Site - Oakland
  • Lexicon Investigational Site - Orange
  • Lexicon Investigational Site - San Diego
  • Lexicon Investigational Site - Santa Monica
  • Lexicon Investigational Site - Tustin
  • Lexicon Investigational Site - Westlake Village

Arizona

  • Lexicon Investigational Site - Tempe
  • Lexicon Investigational Site - Tucson
  • Lexicon Investigational Site - Tucson

Colorado

  • Lexicon Investigational Site - Littleton
  • Lexicon Investigational Site - Littleton
  • Lexicon Investigational Site - Wheat Ridge

Arkansas

  • Lexicon Investigational Site - Little Rock
  • Lexicon Investigational Site - North Little Rock

Alabama

  • Lexicon Investigational Site - Huntsville

Connecticut

  • Lexicon Investigational Site - Waterbury

Florida

  • Lexicon Investigational Site - Boynton Beach

Trial Details

FieldValue
Enrollment Target 373 participants
Start Date 2012-02
Phase Phase 2

Sponsor

Lexicon Pharmaceuticals

56 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01494233

The ClinicalTrials.gov registry entry for NCT01494233 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 373 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 136-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (174% higher). The listed sponsor is Lexicon Pharmaceuticals, which has 56 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Irritable Bowel Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo tablet is the first listed.

NCT01494233 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Arizona, Colorado.

Frequently Asked Questions

What is clinical trial NCT01494233 about?

NCT01494233 is a clinical study titled "A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome". The objective of this study is to evaluate the safety and efficacy of LX1033 over a range of dose levels in subjects with diarrhea-predominant Irritable Bowel Syndrome (IBS).

What is the current status of trial NCT01494233?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 373 participants. The study started on 2012-02.

What conditions does trial NCT01494233 study?

This clinical trial studies the following conditions: Irritable Bowel Syndrome.

What interventions are being tested in trial NCT01494233?

The interventions under investigation include: Placebo tablet (DRUG), 250 mg LX1033 tablets (DRUG).

Who is sponsoring clinical trial NCT01494233?

This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01494233 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Irritable Bowel Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Irritable Bowel Syndrome

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.